DuPont expands probiotics fermentation capacity at Rochester site

Investment at the New York facility brings DuPont's total probiotic fermentation operation to 76,600 sqft

Photo for illustration purpose only

DuPont Nutrition & Health has completed construction on a new, state-of-the-art probiotics fermentation unit at its Rochester facility in New York (US). The 23,600 sqft fermentation addition brings DuPont's total probiotic fermentation operation to 76,600 sqft. According to the company, this is the largest in the world to date.

The unit is part of a multiphase investment of nearly US$100 million to expand probiotics capacity and enhance the company’s ability to deliver high-quality, clinically documented probiotics to dietary supplement and food and beverage manufacturers.

“Completing the construction on our new fermentation unit marks a major milestone in delivering essential innovations for our customers and achieving our ambitious probiotics growth plans,” said Matthias Heinzel, President, DuPont Nutrition & Health.

Heinzel said the company is witnessing a significant rise in demand for probiotics as consumers make health and wellness a daily priority. "We are proud to continue to deliver on our commitment to invest in this fast-growing segment, which can also enable sustainable growth for our customers around the world," he said.

The completion of the capacity expansion comes only days after a research by Italian scientists identified the effect of higher doses of DuPont's multistrain range on developing healthy gut in humans.

The new fermentation unit is fully operational and will serve as a crucial resource in propagating bacteria and enabling high potency, stability and efficacy of probiotics.

Quality is extremely important in probiotic production, and the fermentation unit will also optimise DuPont’s production capability, enabling the company to increase the pace of delivery to customers and the market.

DuPont has been in expansion mode since 2018, when the company completed a probiotics capacity expansion at its Madison site in Wisconsin. The investment was used to upgrade equipment and increase the pace of new product development and significantly improved delivery times on pilot material for clinical trials and customer evaluations.

The company offers the widest range of clinically documented strains. The DuPont Danisco portfolio supports digestive health, immune health, women’s health and more.

The HOWARU products were recognised with a series of outstanding innovation awards in 2018 from various industry organisations. The company is also leveraging its probiotics platform for the development of human milk oligosaccharides (HMOs) as part of a larger microbiome investment strategy.

Companies